# A large scale integrative resource from ENCODE for cancer research

## Introduction

A small fraction of mutations associated with cancer have been well characterized, particularly those in coding regions of key oncogenes and tumor suppressors. However, the overwhelming bulk of mutations in cancer genomes – particularly those discovered over the course of recent large-scale cancer genomics initiatives – lie within non-coding regions. Whether these mutations have substantial functional impacts and drive or affect cancer development or progression remains an open question \cite{26781813}.

Several recent studies have begun to address this question by incorporating limited functional genomics data for variant interpretation \{cite 25261935, 27064257, 27807102}. For example, *Hoadley et al.* integrated five genome-wide platforms and one proteomic platform to uniformly classify various tumor types \{cite 25109877}. *Torchia et al.* integrated various genomic and epigenetic signals to identify promising therapeutic targets in rhabdoid tumors \cite{27960086}. *Lawrence et al.* incorporated large-scale genomics profiles to identify cancer drivers \{cite 23770567}. However, there is no systematic integration of thousands of functional genomic data sets to interpret the cancer genome.

The data and annotation resources developed by ENCODE address this large-scale integration of functional data. Here, we show their relevance in the context of the cancer genome. The main goal of the Consortium is to systematically map the functional elements in the human genome. In the initial release of the ENCODE annotation this was predominantly accomplished using RNA-seq and ChIP-seq assays on a limited number of cell types \cite{22955616}. The new release of ENCODE took two new directions. First, it considerably broadened the number of cell types with the main RNA-seq, ChIP-seq, and DNase-seq assays; the main ENCODE encyclopedia aims to utilize this to provide a overall, unified annotation resource applicable across many cells. Secondly, ENCODE expanded the number of sophisticated assays such as STARR-seq, Hi-C, ChIA-pet, eCLIP and RAMPAGE on several top-tier cell lines, many of which are cancer-associated. This enables precise definitions of enhancers, direct identification of enhancer-target gene links, and the construction of RNA-binding protein (RBP) networks. Here, we perform large-scale integration of these various assays to construct an in-depth cancer related companion resource to the general encyclopedia. We call this the “companion *ENCODE* encyclopedia resource for *C*ancer” (or “EN-CODEC” for short).

## Comprehensive functional characterization by ENCODE data integration

As shown in Fig. 1, many of the encode cell types are relevant to cancer biology. The ENCODE top-tier cell lines provide good models not only for studying gene regulation in detail, but also for understanding cancers of the blood (K562), breast (MCF-7), liver (HepG2), lung (A549), brain (SK-N-SH), and cervix (HeLa-S3). In different contexts, these top-tier cell lines can be "paired" with functional genomics data form normal tissues (often from Roadmap Epigenomics Project) or other immortalized cell lines from corresponding healthy tissue (Fig 1 A). We reconciled multiple related data from many normal cell types to the main tumor cell lines and believe that such comparisons of these "TN-pairs" could help to model the differential gene regulation between tumor and normal tissues. It is worth noting both relating these cell lines to cancers and pairing the tumor-normal matches is approximate in nature and are not intended to substitute the real tumor and normal tissues. Furthermore, many of these pairings have been used in previous analyses \{cite 25144821, 1975513}(Figure 1 A & supp Fig. s2).

It has been doubted for decades that at least a subpopulation of the tumor cells have the ability to self-renew, differentiate, and regenerate (i.e., similar to what is conceptualized in normal stem cells) \cite{24333726}. To build a companion to the main encyclopedia, we started by defining enhancers. We used genomic signal tracks from a battery of 5 to 10 histone modification marks in combination with DNase-seq. These were used as input into CASPER, a machine learning predictor that we developed to integrate the signal shapes of these various signals. We then assembled these predictions with peaks called from STARR-seq experiments, which directly read out candidate enhancers in the genome. Such an integrative approach gives accurate definitions of enhancers (see supplement). We utilized RAMPAGE data to better define promoters, and further linked enhancers to putative promoters using a deep learning algorithm. These potential linkages were then further filtered through the results of Hi-C and ChIA-PET experiments to obtain high confidence enhancer target linkages. It is worth mentioning that EN-CODEC provides enhancers at difference confidence levels, which includes tens of thousands of lenient enhancers from CASPER to only thousands of conserved enhancers supported by expression correlation, STARR-seq, Hi-C, and ChIA-PET experiments. Such categorization of enhancer by different levels of support noticeably benefits various downstream analyses. For example, the power of mutational burden analysis would be significantly increased by only focusing a small number of accurately annotated narrow elements (more details in supplementary file). We also reconciled these enhancers with the main encyclopedia annotations by reporting the overlapped one and providing new IDs to the novel ones. Finally, the conserved enhancer-target linkages, refined promoters, and RNA binding sites from eCLIP experiments within genes constitute a so-called extended gene neighborhood (Fig1 C).

By incorporating the transcription factors (TF) binding profiles from real ChIP-seq experiments, we further linked the conserved enhancers and promoters with their associated TFs to construct extended regulatory networks. First, we built cell-type-specific distal and proximal TF regulatory networks by linking TF to genes, either directly by TF-promoter interactions or indirectly via TF-to-enhancer-to-gene interactions (Fig1 B). We then pruned these networks to include only the strongest edges using another signal shape algorithm called TIP \{cite 22039215}. In paired "tumor-normal" cell lines, we measured the signed, fractional number of edges changing, the rewiring index, and ranked TFs by this. In addition, we merged our cell-type-specific networks to get a generalized network for pan-cancer analysis. For each network, we then arranged all regulators into a hierarchy. TFs are placed into different levels to the degree which they directly regulate the expression of other TFs \{cite 25880651} or are in turn regulated by them. A final hierarchal network structure is shown in Fig1 D. This shows that the top layer TFs are not only enriched in cancer associated genes but also more significantly drive tumor-to-normal gene differential expressions. We also observe that in some situations highly mutated TFs tend to sit at the bottom of the hierarchy.

## Multi-level data integration improves variant recurrence analysis in cancer

One of the most powerful ways of identifying key elements and functional mutations in cancer is with recurrence analysis to discover regions that mutate more than expected. However, somatic mutational processes can be influenced by numerous confounding factors (in the form of both external genomic factors and local sequence context factors), which can result in many false positives or negatives without appropriate correction \{cite 23770567}. In addition, traditional methods often neglect the natural association of different annotation types (e.g. a gene body and its linked enhancer) and evaluate regions separately. Consequently, they sometimes fail to identify mutational signals from distributed yet biologically relevant genomic regions, thereby limiting their functional interpretation.

To address these limitations, we adopt a two-pronged approach for better recurrence analysis. First, we predict an accurate local background mutation rate (BMR) by removing effects of confounding factors in a cancer-specific manner. Specifically, we separated the whole genome into bins (1Mb) and calculated mutation counts under each local context category. For each category, we used a negative binomial regression of the mutation counts against features like replication timing, chromatin accessibility, Hi-C signal, and expression profiles for BMR prediction. In contrast to methods that use unmatched data \{cite 23770567}, our approach automatically selects the most relevant features, thereby providing noticeable improvements in BMR estimation, which significantly benefits recurrence analyses (Fig 2A). Notably it requires the combination of many different genomic features to get such an accurate estimation (Fig 2 B)

Second, rather than separately testing standalone annotation categories, we used our extended gene neighborhoods as joint test units that contain both the coding exons and non-coding regulatory elements (Fig 1C). Such a scheme allows for the accumulation of weak mutational signals distributed across multiple biologically relevant functional elements, which may otherwise be missed if evaluated under individual tests. It should be noted that to maximize the statistical power to pick up highly mutated regions, we only incorporate the most conservative regulatory regions in to the extended gene burdening analysis. We demonstrate that our scheme can effectively remove false positives and discover meaningful regions with higher-than-expected mutation counts (Fig 2C). For example, in the context of chronic lymphocytic leukemia (CLL), our analysis identifies well-known highly mutated genes, such as TP53 and ATM, which has been reported from previous coding region analysis. It also discovered genes that are missed by the exclusive analysis of coding regions, such as BCL6. Note that BCL6 has strong prognostic value with respect to patient survival (Fig. 2D), indicating that the extended gene neighborhood could be used as an annotation set for recurrence analysis. In addition, we can easily generalize this BMR calibration approach for other cancer types beyond the five discussed here, as our model will pick an appropriately matched ENCODE feature type.

## Extensive rewiring events in regulatory network

We integrated the TF binding sites from real ChIP-seq experiments to set up cell-type specific regulatory networks and investigated the role of key regulators in cancer. Here, we utilized 4 main tumor-normal cell line pairings as described earlier to study how the targets of each common TF changed (i.e., rewired) over the course of oncogenic transformation. We first ranked TFs according the “rewiring index” (Fig. 3 A). In leukemia, well-known oncogenes such as MYC and NRF1 were among the top edge gainers, while the well-known tumor suppressor IKZF1is the most significant edge loser (Fig 3A). Mutations in this latter factor serve as a hallmark of various forms of high-risk leukemia \cite{26202931, 26713593, 26069293 }. Interestingly, IKZF1 loss has been found to be associated with well-known BCR-ABL fusion transcript, which is present in K562, and usually confers poor clinical outcome \cite{26069293}. In contrast, several ubiquitously distributed TFs retain their regulatory linkages (Fig 3A). We observed a similar trend in TFs using a distal, proximal, and combined network (see details in supplementary file). The trend was consistent across highly rewired TFs such as BHLHE40, JUND, and MYC in lung, liver, and breast cancers (Fig 3).

In addition to the simple direct TF to gene connection-based model, the rewiring index was also evaluated using more complex gene community model. The targets within the TF regulatory network were characterized by heterogeneous network modules (so called “gene communities”), which usually come from multiple biologically relevant genes. Instead of directly measuring the TF’s target changes for each gene, we determined the change in gene communities via a mixed-membership model. This enabled us to evaluate each TF’s overall association changes to these gene communities in tumor and normal cells. Similar rewiring patterns were observed using this model (Fig 3A).

Hence, we tested whether the gain or loss events from the normal to tumor transition will result in a network that is more similar or different from those in stem cells like H1-hESC. Interestingly, we found the majority of the cancer associated gainer genes were changing away from H1-hESC cells while the loser group in tumor are more likely to move toward H1-hESC cells.

We find that the majority of rewiring events are associated with noticeable gene expression and chromatin status changes, but not necessarily with variant-induced motif loss or gain events (Fig. 3A). This is consistent with previous discoveries that most non-coding risk variants are not well-explained by the current model \cite{25363779}. For example, JUND is a top gainer in CLL. The majority of its gained targets in tumor cell lines demonstrate higher gene expression, stronger active and weaker repressive histone modification mark signals. We found a similar trend for the rewiring events associated with JUND in liver cancer.

Next, we extended our network analysis in a pan-cancer fashion by merging the cell-type-specific networks for both TFs and RBPs. Then using a machine learning method, we integrated 8,202 tumor expression profiles from TCGA to systematically search for the TFs and RBPs that most strongly drive tumor-specific expression patterns. For each patient, our method tests to the degree a regulators’ regulation potentials are sufficiently correlated with their targets’ tumor-to-normal expression changes. We then calculated the percentage of patients with these relationships in each cancer type and presented the overall trends for key TFs and RBPs in Fig. 4A.

We find that the target genes of MYC are significantly up-regulated in numerous cancers, which is consistent with its well-known role as an oncogenic TF and a transcription activator \cite{22464321}. We further validate MYC’s regulatory effect through knock down experiments (Fig 4). Consistent with our predictions, the expression of MYC targets is significantly reduced after MYC knockdown (Fig 4A). After confirming the importance of MYC, we use the regulatory network to understand how MYC works with other TFs. We first looked at all triplets involving MYC by requiring that a second TF both interacts and shares a common target with MYC. In all cancer types, we found that MYC’s expression levels are positively correlated with the expressions of most of its targets, while the second TF shows only a limited influence as determined from partial correlations. We then investigated the exact structure of such regulatory relationships. The most common triplet interaction type is a well-understood feed-forward loop (FFL) structure in which MYC regulates both the common target and the second TF. Most of these FFLs involve well-known MYC partners such as Max and Mxl1. However, we also discovered that many involve another factor called NRF1. Upon further study, we found that that the MYC-NRF1 FFL relationships were mostly coherent ("amplifying") FFLs. We further studied these FFLs by forming these triplets into a logical gate, in which the two TFs act as inputs and the target gene expression represents the output \{cite 25884877}. We can show that the predominant number of these gates follow either OR or MYC-always-dominant logic. Thus, the ENCODE regulatory network not only helps find key regulators, but also to really demonstrate how they work in combination with other regulators.

We also analyzed the RBP network derived from ENCODE eCLIP data and found key regulators associated with cancer. For example, the ENCODE eCLIP experiment has profiled many SUB1 peaks on the 3’UTR regions of genes, and we find that the predicted targets of the RBP SUB1 were significantly up-regulated in many cancer types (Fig. 4C). As a RBP, SUB1 has not been associated with cancer before. We thus validated this new association in liver cancer. After knocking down SUB1 in HepG2 cells, its predicted targets are also down-regulated relative to other genes (Fig. 4D). In addition, we found that the decay rate of SUB1 target genes are significantly shorter than non-targets (Fig. 4C). These results indicate that SUB1 may bind to 3’UTR regions to stabilize transcripts. Moreover, we found that the up-regulation of SUB1 target genes is correlated with a poorer patient survival in other cancer types such as lung cancer (Fig. 4).

## Step-wise prioritization schemes pinpoint deleterious SNVs in cancer

Summarizing the analysis described above, EN-CODEC consists of number annotation resources: (1) a BMR model with matching procedure and a list of regions with higher-than-expected mutations in various cancers, (2) accurately determined enhancers, promotors and enhancer-target-gene linkages by integrating tens of different functional assays and their comparison with those in ENCODE encyclopedia; (3) extended gene neighborhoods, (4) tumor-normal differential expression and chromatin changes, (5) a regulatory network of TFs; (6) the TF’s position in the network hierarchy and rewiring status; (7) an analogous but less annotated network for RBPs. Collectively, these resources allow us to prioritize key features as being associated with oncogenesis. The workflow in Fig. 5A describes this prioritization scheme in a systematic fashion. We first search for key regulators that are frequently rewired, located in network hubs or at top of the network hierarchy, or significantly driving expression changes in cancer. We then prioritize functional elements that are associated with top regulators, undergo large regulatory changes in terms of expression levels, TF binding, and chromatin status, or are highly mutated in tumors. Finally, on a nucleotide level, we can pinpoint impactful SNVs for small-scale functional characterization by their ability to disrupt or create specific binding sites, or which occur in positions under strong purifying selection.

Using this framework, as we described above, we subject a number of key regulators, such as MYC and SUB1, to knockdown experiments to validate their regulatory effects in particular cancer contexts (Fig 4D). Next here, we also identified several candidate enhancers in noncoding regions, associated with breast cancer, and validated their ability to influence transcription using luciferase assays in MCF7. We selected key SNVs, based on significantly recurrent mutations in breast cancer cohorts, within these enhancers that are important for controlling gene expression. Of the eight motif-disrupting SNVs that we tested, six showed consistent up- or down-regulation relative to the wild type in multiple biological replicates. One particularly interesting example, illustrating the unique value of ENCODE data integration, is in the intronic region of CDH26 in chromosome 20 (Fig. 5C). Both histone modification and chromatin accessibility (DNase-seq) signals indicated an active regulatory role in MCF7, which was further confirmed as an enhancer by both CASPER and ESCAPE (STARR-seq) (Fig. 5D). Hi-C and ChIA-PET data indicated that the region is within a topologically associated domain (TAD) and validated a regulatory linkage to the downstream breast-cancer-associated gene SYCP2 \cite{26334652, 24662924}. We observed massive binding events from TFs in this region in MCF-7. Motif analysis predicts that the particular mutations found in the cohorts can significantly disrupt the binding affinity of several TFs, such as FOSL2, in this region (Fig. 5D). Luciferase assays demonstrate that this mutation introduces a 3.6-fold reduction in expression relative to wild type expression levels, indicating a strong repressive effect on this enhancer’s functionality.

## Conclusion

This study highlights the value of our companion to the encyclopedia as a resource for cancer research. First, we show that, by integrating many different types of assays on a large scale, we can achieve a very accurate annotation of ENCODE top-tier cell lines and relate them to cancer to build up extensive regulatory networks. It is worth mentioning that rather than imputed binding sites from motif analysis \cite{25409825}, our network are built on results from hundreds of ChIP-seq experiments.We did notice that the representative tumor and normal cell types used here are very rough. However, cancer is such a heterogeneous disease that even the tumor cells from one patient usually shows distinct molecular, morphological, and genetic profiles \cite{24048065}. It is difficult to obtain a "perfect" match even from data of real tumor and normal tissues. Then we show how comparisons within this resource itself can illuminate potential regulatory changes in cancer (e.g. key rewiring TFs). Next, we show how the resource can be generalized into a pan-cancer regulatory network and BMR framework to help interpret patient data from cancer cohorts, both gene expression and mutation data. Finally, we show how we can leverage the companion resource to provide a prioritization scheme to pinpoint key regulatory elements and SNVs for small-scale follow-up. This study underscores the value of large-scale data integration, and we note that expanding this approach (either by integrating additional data types and/or using tumor mutation and expression data on a larger scale) is straightforward. We also anticipate that an additional step would be to carry out many of the ENCODE assays on specific tissues and tumor samples. Though volume of material needed for such analyses may present challenges, we show that such a framework is technically feasible and provides further opportunities for the future.